Effects of Subclinical Hypothyroidism on Maternal and Perinatal Outcomes during Pregnancy: A Single-Center Cohort Study of a Chinese Population

Liang-Miao Chen¹,², Wen-Jun Du¹,², Jie Dai¹, Qian Zhang¹, Guang-Xin Si¹, Hong Yang¹, En-Ling Ye¹, Qing-Shou Chen¹, Le-Chu Yu¹, Chi Zhang²,³, Xue-Mian Lu¹,²,³

¹Department of Endocrinology, Third Affiliated Hospital, Wenzhou Medical University, Ruian, Zhejiang, China, ²Chinese-American Research Institute for Diabetic Complications, Wenzhou Medical University, Wenzhou, China, ³Ruian Center of the Chinese-American Research Institute for Diabetic Complications, Third Affiliated Hospital, Wenzhou Medical University, Wenzhou, China

Abstract

Objective: Adverse maternal outcomes and perinatal complications are closely associated with overt maternal hypothyroidism, but whether these complications occur in women with subclinical hypothyroidism (SCH) during pregnancy remains controversial. The aim of this study was to evaluate the effects of SCH on maternal and perinatal outcomes during pregnancy.

Methods: A prospective study of data from 8012 pregnant women (371 women with SCH, 7641 euthyroid women) was performed. Maternal serum samples were collected in different trimesters to examine thyroid hormone concentrations. SCH was defined as a thyroid stimulating hormone concentration exceeding the trimester-specific reference value with a normal free thyroxine concentration. The occurrence of maternal outcomes, including gestational hypertension (GH), gestational diabetes mellitus, placenta previa, placental abruption, prelabor rupture of membranes (PROM), and premature delivery; and perinatal outcomes, including intrauterine growth restriction (IUGR), fetal distress, low birth weight (LBW; live birth weight ≤2500 g), stillbirth, and malformation, was recorded. Logistic regression with adjustment for confounding demographic and medical factors was used to determine the risks of adverse outcomes in patients with SCH.

Results: Compared with euthyroid status, SCH was associated with higher rates of GH (1.819% vs. 3.504%, \(P = 0.020\); \(\chi^2 = 7.345\); odds ratio (OR), 2.243; 95% confidence interval (CI), 1.251–4.024), PROM (4.973% vs. 8.625%, \(P = 0.002\); \(\chi^2 = 72.102\); adjusted OR, 6.014; 95% CI, 3.975–9.099), IUGR (1.008% vs. 2.965%, \(< 0.001\); \(\chi^2 = 13.272\); adjusted OR, 3.336; 95% CI, 1.745–6.377), and LBW (1.885% vs. 4.582%, \(P < 0.001\); \(\chi^2 = 13.558\); adjusted OR, 2.919; 95% CI, 1.650–5.163).

Conclusions: The results of this study indicate that pregnant women with SCH had increased risks of GH and PROM, and their fetuses and infants had increased risks of IUGR and LBW. Thus, routine maternal thyroid function testing is necessary to improve maternal and perinatal outcomes.
development impairment, are the main complications induced by maternal hypothyroidism during early pregnancy [3–7]. Thyroid hormone deficiency beyond the first trimester also cannot be ignored, although fetal thyroid hormones are functional at this time. For example, triiodothyronine activates enzymes important for neurodevelopment in late pregnancy [8]. Other adverse maternal outcomes and perinatal complications associated with overt maternal hypothyroidism include miscarriage, preeclampsia, preterm labor, and fetal death [9–11]. However, hypothyroidism is not readily recognized because it usually manifests as non-specific symptoms. SCH is often missed in pregnant women, although its prevalence is about 2–3% [12–15]. This condition has been associated with neurodevelopmental disorders in fetuses and infants and several adverse maternal outcomes, including gestational diabetes mellitus (GDM), preeclampsia, placental abruption, and preterm delivery [3,5,13,14,16,17]. Women who have been previously diagnosed with SCH are at increased risk of stillbirth and GDM in subsequent pregnancies [14].

However, no consensus has been reached about the need for universal thyroid function screening and the treatment of SCH during pregnancy. The American College of Obstetricians and Gynecologists and the clinical practice guidelines of the Endocrine Society recommended the examination of thyroid function only in women with symptoms of thyroid disease or previous histories of thyroid disease and other associated conditions [18,19]. However, this screening protocol is not sufficient because pregnant women with SCH are often asymptomatic, with no history of immune disorder. In China, the recognition and treatment of thyroid disorder in pregnant women is also insufficient and few studies have examined the possible effects of SCH on maternal and perinatal outcomes in large Chinese populations.

In the present study, universal screening of thyroid function was conducted in a Chinese population. The prevalence of SCH and associated maternal and perinatal outcomes were determined, and the risks of adverse outcomes associated with SCH were assessed.

**Materials and Methods**

**Ethics statements**

This study was conducted at the Third Hospital Affiliated of Wenzhou Medical University, Zhejiang, China, and the study protocol was approved by the hospital’s institutional review board. Written informed consents were obtained from all enrolled subjects prior to the study. The privacy of all subjects was guaranteed.

**Study population and thyroid function screening**

Between February 2009 and February 2012, 8012 pregnant women were enrolled in this prospective study. All subjects were screened and gave birth at the hospital, and had resided in the local area for at least 5 years. Women with the following conditions were excluded: overt thyroid disorder, previous or present use of thyroxin or anti-thyroid drugs, other autoimmune disease, congenital heart disease, and elevated serum transaminase or creatinine level (reference ranges: glutamic-pyruvic transaminase, 0–55 IU/L; glutamic oxalacetic transaminase, 6–60 IU/L; serum creatinine, 40–106 umol/L).

Thyroid function was tested at the first antenatal examination. Among 8012 women recruited for this study, 1124 (14.03%) participants were tested in the first trimester, 2640 (32.95%) were tested in the second trimester, and 4248 (53.02%) were tested in the third trimester. Information about the following demographic and clinical characteristics was collected through questionnaires administered during examination: demographic characteristics (e.g., age, address, occupation, educational level, income), medical history (menstrual history, childbearing history, other diseases, medication use), health behavior (smoking and exposure to husbands’ smoking, alcohol consumption), general physical parameters (body weight, blood pressure, cardiopulmonary function, edema), obstetric parameters (fetal position, abdominal girth, fetal heart sound, pelvic examination when necessary), and laboratory assessments (screening for GDM, HIV, syphilis, routine blood and urinary tests, hepatic and renal functions, blood type, electrocardiography, electronic fetal monitoring). All data were kept in a computerized database.

**Laboratory assays and diagnosis of SCH**

Fasting venous blood samples were collected in the morning from all participants. Serum was isolated after centrifugation and stored at –80°C until testing. Serum TSH and fT4 concentrations were measured by electrochemiluminescence immunoassay (DX2800; Beckman, Bremen, Germany) and associated diagnostic kits. Inter- and intra-assay coefficients of variation for each hormone were <10%. The assessment of thyroid function was based on the following local trimester-specific reference values (2.5th–97.5th percentiles) [20]: first trimester, TSH 0.09–3.47 mIU/L and fT4 6.00–12.25 ng/L; second trimester, TSH 0.20–3.81 mIU/L and fT4 4.30–9.74 ng/L; and third trimester, TSH 0.67–4.99 mIU/L and fT4 4.56–8.50 ng/L. SCH was defined as a TSH concentration exceeding the trimester-specific reference value in combination with a normal fT4 concentration. Pregnant women with normal TSH and fT4 levels were considered to be euthyroid and served as control subjects.

**Definition of maternal and fetal outcomes**

All participants underwent monthly antenatal examinations during gestation and delivery until they were discharged from the hospital. Maternal and perinatal outcomes based on specific guidelines were recorded during this period.

The following maternal outcomes were diagnosed based on individual guidelines and documented. Gestational hypertension (GH) was defined as systolic pressure >140 mmHg and/or diastolic pressure >90 mmHg after 20 weeks of gestation, with no previous history of hypertension, including preeclampsia and eclampsia [21]. Preecclampsia was defined as persistent elevated blood pressure (systolic pressure ≥140 mmHg, diastolic pressure ≥90 mmHg) with proteinuria and eclampsia as the appearance of seizure or coma in a patient with GH. GDM was defined as a plasma glucose concentration ≥95 mg/dL after fasting, ≥180 mg/dL at 1 h after a 100-g oral glucose tolerance test (OGTT), and/or ≥155 mg/dL at 2 h after a 100-g OGTT, regardless of gestational age [22]. Placenta previa was defined as the partial or complete insertion of the placenta in the lower uterine segment and placental abruption as the separation of the placenta from the uterine lining before labor [23]. Preterm rupture of membranes (PROM) was defined as the rupture of the amniotic sac and chorion membrane prior to the onset of labor [24,25]. A delivery occurring between 28 and 37 completed weeks of gestation was considered premature [26,27].

The following perinatal outcomes were assessed and documented. Intrauterine growth restriction (IUGR) was defined as an estimated fetal weight below the 10th percentile for gestational age [28,29]. Fetal distress was defined as fetal heartrate <120 bpm or >160 bpm, presence of meconium, signs of abnormal fetal movement, and fetal scalp pH<7.2 [30]. The documentation of fetal distress was based on the presence of fetal distress signs before or during labor and associated complications [31]. Low birth weight (LBW) was defined as a live birth weight ≤2500 g [32].
Stillbirth was diagnosed when fetal death occurred after the 20th week of pregnancy [33]. Any malformation of the eyes, ears, or face; nervous, circulatory, urinary, reproductive, musculoskeletal system, or any other organ was recorded.

Statistical analysis

All data are expressed as means ± standard deviations or numbers and percentages. Statistical analysis was performed using the SPSS 16.0 software. Student’s t-test was used to compare continuous variables (maternal age, gestational age at delivery, TSH and fT4 concentrations) and the chi-squared test was used to compare categorical measures (educational level, parity, mode of delivery, exposure to husbands’ smoking, all maternal and perinatal outcomes). The risks of adverse outcomes in patients with SCH were determined by logistic regression and represented as odds ratios (ORs) and 95% confidence intervals (CIs), with adjustment for various confounding factors (maternal age, educational level, parity, gestational age at delivery, mode of delivery, exposure to husbands’ smoking). Maternal SCH and several other possible risk factors, such as maternal age, parity (nulliparity vs. multiparity), and exposure to husbands’ smoking (yes/no), were introduced into the logistic regression model to identify factors associated with adverse outcomes. P<0.05 was considered to be statistically significant.

Results

Maternal demographic characteristics

Maternal demographic characteristics are shown in Table 1. Of the 8012 women, 7641 (95.37%) had TSH and fT4 values within the normal reference ranges in the trimester of testing and were considered to be euthyroid, whereas 371 (4.63%) had high TSH levels coupled with normal fT4 levels and were considered to have SCH. Mean maternal age, education level, parity, gestational age at delivery, and delivery modes were similar in the two populations (Table 1). No participant smoked or drank alcohol during pregnancy, but more than 40% of women in both groups (euthyroid, 43.16%; SCH, 44.74%; P = 0.887) were exposed to their husbands’ smoking.

Table 1. Maternal demographic characteristics.

|                          | Euthyroid (n=7641) | SCH (n=371) | P     |
|--------------------------|--------------------|------------|-------|
| Maternal age (years)     | 27.12 ±0.05        | 26.33 ±0.24| 0.243 |
| Educational level        |                    |            | 0.970 |
| Primary school           | 607 (7.94%)        | 35 (9.43%) |       |
| Middle school            | 4465 (58.43%)      | 238 (64.15%)|      |
| College or university    | 2327 (30.45%)      | 84 (22.64%)|       |
| Parity                   |                    |            | 0.856 |
| Nulliparity              | 6241 (81.68%)      | 299 (80.59%)|      |
| Multiparity              | 1400 (18.32%)      | 72 (19.41%)|       |
| Gestational age at delivery (weeks) | 38.99 ±0.02 | 39.05 ±0.09 | 0.087 |
| Mode of delivery         |                    |            | 0.121 |
| Vaginal                  | 4876 (63.81%)      | 246 (66.31%)|      |
| Forceps                  | 16 (0.21%)         | 2 (0.54%)  |       |
| Cesarean                 | 2749 (35.98%)      | 123 (33.15%)|      |
| Exposure to husbands’ smoking | 3298 (43.16%) | 166 (44.74%)| 0.887 |

SCH, subclinical hypothyroidism.

Thyroid function in different trimesters among women with SCH

Table 2 presents the TSH and fT4 concentrations of patients with SCH in different trimesters. The TSH concentration was significantly lower in the first trimester than in the third trimester (P<0.001). The fT4 concentration was higher in the first trimester than in the second and third trimesters (P<0.001).

Maternal outcomes in the euthyroid and SCH groups

Maternal outcomes in the two groups are compared in Table 3. No significant difference in the incidence of GDM, placenta previa, placental abruption, or preterm birth was observed between groups. The incidences of GH and PROM were significantly higher in women with SCH than in euthyroid women (3.504% vs. 1.819%, P = 0.020; 8.625% vs. 4.973%, P = 0.002).

Perinatal outcomes in the euthyroid and SCH groups

Comparisons of selected perinatal outcomes are shown in Table 4. No significant difference in the incidence of fetal distress or stillbirth was observed between the SCH and euthyroid groups. IUGR was more frequent in women with SCH than in euthyroid women (2.965% vs. 1.008%, P<0.001). More LBW infants were delivered in the SCH group than in the euthyroid group (4.582% vs. 1.885%, P<0.001). Twenty-eight fetuses and infants had obvious malformation, and this outcome was observed more often in the SCH group than in the euthyroid group (1.078% vs. 0.314%, P<0.05).

Trimester-stratified maternal and perinatal outcomes

Tables 5–7 present comparisons of maternal and perinatal outcomes between euthyroid women and those with SCH in different trimesters. No significant difference in outcomes was noted between the two groups of women who underwent thyroid function testing in the first trimester (Table 5). However, among those tested in the second trimester, women with SCH had significantly higher incidences of stillbirth (3.704% vs. 0.155%, P = 0.006) and malformation (3.704% vs. 0.425%, P = 0.028). Among those tested in the third trimester, the incidences of
Effects of SCH on Maternal and Perinatal Outcomes

Table 2. TSH and fT4 concentrations in women with SCH by trimester.

| Trimester | TSH concentration (mIU/L) | fT4 concentration (ng/L) |
|-----------|---------------------------|-------------------------|
| First     | 4.38±0.14*                | 8.33±0.18               |
| Second    | 4.73±0.16                 | 6.64±0.15*              |
| Third     | 6.62±0.13                 | 6.68±0.55*              |

TSH, thyroid stimulating hormone; fT4, free thyroxine; SCH, subclinical hypothyroidism.

PROM (10.448% vs. 6.055%, \( P = 0.004 \)), IUGR (4.104% vs. 1.080%, \( P < 0.001 \)), and LBW (5.970% vs. 2.111%, \( P < 0.001 \)) were significantly higher in women with SCH than in euthyroid women. The incidence of GH was also higher in women with SCH than in euthyroid women in the third trimester, although this difference was not significant (4.478% vs. 2.538%, \( P = 0.056 \)).

Estimated risks of maternal SCH in association with adverse outcomes

The results of logistic regression analysis of possible risk factors associated with adverse outcomes are displayed in Table 3. After adjusting for maternal age, parity, gestational age at delivery, and exposure to husbands' smoking, SCH was found to increase the likelihood of several maternal adverse outcomes. The risk of GH was more than two-fold greater among mothers with SCH (\( \chi^2 = 7.345; \) adjusted OR, 2.243; 95% CI, 1.251-4.024; \( P = 0.007 \)). Pregnant women with SCH had a higher risk of developing PROM (\( \chi^2 = 72.102; \) adjusted OR, 6.014; 95% CI, 3.973-9.099; \( P < 0.001 \)). Maternal SCH was also identified as a risk factor for fetal IUGR (\( \chi^2 = 13.272; \) adjusted OR, 3.336; 95% CI, 1.745-6.377; \( P < 0.001 \)) after adjusting for confounding factors. Nearly three-fold more LBW infants were born to mothers with SCH compared with euthyroid women (\( \chi^2 = 13.558; \) adjusted OR, 2.919; 95% CI, 1.650-5.163; \( P < 0.001 \)) after adjustment. However, the association of perinatal malformation with SCH was not significant in the adjusted analysis (\( P = 0.101 \)).

Discussion

The current study was performed to gain insight into the impacts of SCH on maternal and perinatal outcomes. In our study sample, 4.63% of pregnant women were diagnosed with SCH. Pregnant women with SCH had increased risks of developing GH and PROM. Fetuses and infants of women with SCH had significantly higher risks of IUGR and LBW compared with those born to euthyroid mothers.

Universal thyroid function screening before pregnancy is not currently recommended; thyroid hormone concentrations are typically measured only in women at high risk of thyroid disorders, and screening for thyroid dysfunction in early pregnancy is controversial [19]. Some clinicians support the testing of all pregnant women at the first maternity visit, and certainly by the 9th week of gestation, whereas others examine only women at high risk. However, this targeting of high-risk women has been shown to overlook a significant proportion of affected women. Vaidhya et al. [34] reported that targeted testing of women with personal and/or family histories of thyroid or other autoimmune dysfunction missed approximately one-third of pregnant women with overt hypothyroidism or SCH in a sample of 1500 patients. Another study suggested that targeted testing overlooks more than half of thyroid abnormalities [35]. Thus, a more extensive screening protocol for thyroid disorders may be required. Moreover, given the one child per family policy in China, pregnant women prefer to undergo thorough screening to identify any abnormality potentially affecting the health of their precious single child [36]. Thyroid function testing in pregnant women at the first prenatal visit is thus a reasonable approach in China.

Pregnancy has pronounced effects on thyroid physiology [37,38]. Total concentrations of triiodothyronine and thyroxine, major hormones secreted by the thyroid, increase during pregnancy because of elevated thyroxin-binding globulin concentration. Human chorionic gonadotropin (HCG), a weak thyroid activator, is elevated during the first trimester of pregnancy and can trigger a slight decrease in the serum TSH concentration [39]. Thus, the serum TSH concentration is low in the first trimester, and then increases significantly in the second and third trimesters [37]. The fT4 level typically increases during the period of peak HCG level in the first trimester, and declines later in pregnancy [37]. Thus, the use of gestational-age–specific threshold values for

| Outcome          | Euthyroid (n=7641) | SCH (n=371) | \( P \) |
|------------------|--------------------|-------------|-------|
| GH               | 139 (1.819%)       | 13 (3.504%) | 0.020 |
| GDM              | 268 (3.743%)       | 8 (2.156%)  | 0.112 |
| Placenta previa  | 16 (0.209%)        | 0 (0%)      | 0.378 |
| Placental abruption| 13 (0.170%)    | 1 (0.270%)  | 0.654 |
| PROM             | 380 (4.973%)       | 32 (8.625%) | 0.002 |
| Premature delivery| 268 (3.507%)      | 13 (3.504%) | 0.997 |

SCH, subclinical hypothyroidism; GH, gestational hypertension; GDM, gestational diabetes mellitus; PROM, prelabor rupture of membranes.
thyroid hormones is essential for the accurate diagnosis of thyroid disorders, such as SCH [3,40]. Trimester-specific reference values for thyroid function have been established for the Chinese population using women with normal singleton pregnancies [20]. The incidence of SCH among pregnant women in our study (4.63%), defined using these reference values, is similar to previously reported values (2–5%) [41].

The impacts of SCH on maternal and perinatal outcomes have not been clearly identified. Some studies [12,42] revealed that SCH did not result in poor maternal outcomes, whereas other investigations demonstrated that SCH was associated with several obstetric complications, including GH, IUGR, placental abruption, and GDM [15–17,43]. Thyroid hormones regulate cardiovascular activities and blood pressure, and long-term thyroid hormone disorder results in cardiovascular dysfunction [44–48]. In non-pregnant adults, SCH was also associated with the higher incidence and recurrence of congestive heart failure compared with euthyroid adults [48]. In the current study, the incidence of GH was higher in women with SCH than in euthyroid women in the third trimester, although this difference was not significant. More importantly, when data from all three trimesters were analyzed together, the incidence of GH was significantly higher in women with SCH than in euthyroid women after adjusting for confounding factors, such as maternal age, parity, gestational age at delivery, and exposure to husband’s smoking. This association has been supported by molecular research documenting decreased nitric oxide secretion and impaired endothelium-related vasodilation in patients with SCH [49], which could be reversed by thyroxine replacement.

A higher risk of GDM associated with SCH has also been reported. In a large population-based study involving 24,883 women, the risk of GDM increased markedly with elevated TSH concentration during pregnancy [15]. Although another study by Cleary-Goldman and colleagues [12] documented a higher risk of GDM associated with overt hypothyroidism (adjusted OR, 1.7; 95% CI, 1.02–2.84), no such association was observed in patients with SCH. In the present study, we also failed to demonstrate that SCH affected GDM development. This difference may be due to the use of different cutoff values to define SCH (TSH concentration >4.13 mIU/L with no correction for gestational age in Tudela et al. [15] vs. gestational-age–specific ranges of TSH concentration in the present study).

The present study documented a higher risk of PROM in pregnant women with SCH, especially in the third trimester, which did not differ according to maternal age, parity, or smoking status. Although no other study has reported that SCH is associated with an increased risk of PROM, several reports have suggested that this risk is higher in patients with overt hypothyroidism. A higher incidence of PROM was observed in patients with hypothyroidism than in healthy pregnant women (11.7% vs. 7.8%, P<0.001) in a large population-based cohort study [50]. Davis et al. [51] also found a high incidence of PROM in subsequent euthyroid pregnancies among previously overtly hypothyroid women. In our sample, the incidence of IUGR was

| Outcome               | Euthyroid (n=7641) | SCH (n=371) | P     |
|-----------------------|--------------------|-------------|-------|
| IUFRI                 | 77 (1.008%)        | 11 (2.965%) | <0.001|
| Fetal distress        | 288 (3.769%)       | 17 (4.582%) | 0.424 |
| LBW                   | 144 (1.885%)       | 17 (4.582%) | <0.001|
| Stillbirth            | 21 (0.275%)        | 2 (0.539%)  | 0.289 |
| Malformation          | 24 (0.314%)        | 4 (1.078%)  | 0.038 |

SCH, subclinical hypothyroidism; IUFRI, intrauterine growth restriction; LBW, low birth weight.

doi:10.1371/journal.pone.0109364.t004

Table 5. Maternal and perinatal outcomes of euthyroid women and those with SCH in the first trimester.

| Outcome               | Euthyroid (n=1075) | SCH (n=49) | P     |
|-----------------------|--------------------|-------------|-------|
| GH                    | 11 (1.023%)        | 0 (0%)      | 1     |
| GDM                   | 69 (6.419%)        | 1 (2.041%)  | 0.360 |
| Placenta previa       | 0 (0%)             | 0 (0%)      | 1     |
| Placental abruption   | 1 (0.001%)         | 0 (0%)      | 1     |
| PROM                  | 35 (3.256%)        | 2 (4.082%)  | 1     |
| Premature delivery    | 33 (3.070%)        | 0 (0%)      | 0.213 |
| IUFRI                 | 6 (0.558%)         | 0 (0%)      | 1     |
| Fetal distress        | 29 (2.698%)        | 2 (4.082%)  | 0.895 |
| LBW                   | 14 (1.302%)        | 1 (2.041%)  | 0.49  |
| Stillbirth            | 5 (0.465%)         | 0 (0%)      | 1     |
| Malformation          | 3 (0.279%)         | 0 (0%)      | 1     |

SCH, subclinical hypothyroidism; GH, gestational hypertension; GDM, gestational diabetes mellitus; PROM, prelabor rupture of membranes; IUFRI, intrauterine growth restriction; LBW, low birth weight.

doi:10.1371/journal.pone.0109364.t005
almost four-fold greater in fetuses of mothers with SCH than in euthyroid mothers after adjustment for confounding factors and smoking status. Similar observations have been described in other reports. Ohashi et al. [39] reported IUGR in 25% of pregnancies involving maternal thyroid dysfunction, and 16.52% (19/115) of IUGR cases occurred in the SCH group. We also found that SCH was associated with a significant risk of LBW, as reported by Leung et al. [52]. This association was not very evident in the first and second trimesters, but the incidence of LBW was almost three times higher among women with SCH than among euthyroid women in the third trimester, which could also be due the higher incidence of IUGR in those women. These findings suggest that the increased rate of LBW in infants born to women with SCH is related to this thyroid disorder. Because IUGR and LBW are reported risk factors for subnormal neurobehavioral performance and intellectual development [53–55], possible links between IUGR and LBW in infants born to mothers with SCH and impaired psychological development have been proposed [6,56]. Although we found that the incidence of malformation was higher in infants born to women with SCH than in those born to euthyroid women, particularly in the second trimester, this association was not significant after adjustment for confounding factors. Casey et al. [16] and Mannisto et al. [57] also suggested that maternal thyroid disorder was not associated with an increased rate of fetal malformation. Su and colleagues [58] reported higher risks of circulatory system (one case, 11.1%) and musculoskeletal (two cases, 4.7%) malformations in the fetuses of women with hypothyroidism. However, their sample was small and the higher incidence of fetal malformation was observed in women with clinical hypothyroidism (higher TSH level and lower fT4 level) and isolated hypothyroidism (normal TSH level and low fT4 level). In the present study, the stillbirth rate was higher among women with SCH than among euthyroid women in the second trimester, but no significant difference was observed in analysis of the entire sample. The association of a higher stillbirth rate with SCH in the second trimester may be the result of a combination of various adverse complications. Casey et al. [16] also found no difference in stillbirth rate according to thyroid status. Although an increased stillbirth rate in hypothyroid women with TSH levels $>10$ mU/L has been previously reported, SCH

Table 6. Maternal and perinatal outcomes of euthyroid women and those with SCH in the second trimester.

| Outcome          | Euthyroid (n = 2586) | SCH (n = 54) | P  |
|------------------|----------------------|--------------|----|
| GH               | 27 (1.044%)          | 1 (1.851%)   | 0.441 |
| GDM              | 127 (4.945%)         | 2 (3.704%)   | 1   |
| Placenta previa  | 3 (0.116%)           | 0 (0%)       | 1   |
| Placental abruption | 2 (0.773%)       | 0 (0%)       | 1   |
| PROM             | 109 (4.215%)         | 2 (3.703%)   | 1   |
| Premature delivery| 66 (2.126%)          | 1 (1.852%)   | 0.746 |
| IUGR             | 28 (1.083%)          | 0 (0%)       | 1   |
| Fetal distress   | 85 (3.287%)          | 0 (0%)       | 0.335 |
| LBW              | 46 (1.779%)          | 0 (0%)       | 1   |
| Stillbirth       | 4 (0.155%)           | 2 (3.704%)   | 0.006 |
| Malformation     | 11 (0.425%)          | 2 (3.704%)   | 0.028 |

SCH, subclinical hypothyroidism; GH, gestational hypertension; GDM, gestational diabetes mellitus; PROM, prelabor rupture of membranes; IUGR, intrauterine growth restriction; LBW, low birth weight.

doi:10.1371/journal.pone.0109364.t006

Table 7. Maternal and perinatal outcomes of euthyroid women and those with SCH in the third trimester.

| Outcome          | Euthyroid (n = 3980) | SCH (n = 268) | P  |
|------------------|----------------------|--------------|----|
| GH               | 101 (2.538%)         | 12 (4.478%)  | 0.056 |
| GDM              | 72 (1.809%)          | 5 (1.866%)   | 0.815 |
| Placenta previa  | 13 (0.334%)          | 0 (0%)       | 1   |
| Placental abruption | 10 (0.257%)       | 1 (0.373%)   | 0.512 |
| PROM             | 241 (6.055%)         | 28 (10.448%) | 0.004 |
| Premature delivery| 173 (4.347%)         | 11 (4.104%)  | 0.85 |
| IUGR             | 43 (1.080%)          | 11 (4.104%)  | <0.001 |
| Fetal distress   | 169 (4.246%)         | 15 (5.597%)  | 0.293 |
| LBW              | 84 (2.111%)          | 16 (5.970%)  | <0.001 |
| Stillbirth       | 12 (0.301%)          | 0 (0%)       | 1   |
| Malformation     | 10 (0.251%)          | 2 (0.746%)   | 0.056 |

SCH, subclinical hypothyroidism; GH, gestational hypertension; GDM, gestational diabetes mellitus; PROM, prelabor rupture of membranes; IUGR, intrauterine growth restriction; LBW, low birth weight.

doi:10.1371/journal.pone.0109364.t007
The strengths of this investigation are related to the prospective examination of a large population-based cohort. The major finding of this study was that SCH, a relatively common disorder in pregnant women, has pronounced effects on maternal and fetal outcomes. Specifically, SCH can lead to GH and PROM in mothers, and higher incidences of IUGR and LBW in infants. However, this study has several limitations. First, it was based on data from a single center. Second, the impacts of anti-thyroid antibodies, including thyroglobulin and thyroid peroxidase antibodies, were not taken into account when assessing maternal and fetal outcomes. Our results may have been affected by the presence of thyroid antibodies, which may increase the possibility of developing hypothyroidism or be directly associated with adverse obstetric outcomes, regardless of thyroid hormone status [19,59]. Third, because the serum TSH level may be elevated in overweight and obese women, SCH may be mistakenly diagnosed in such patients [60]. Body mass index was not accounted for in this study, which may have affected the results. Finally, the interplay of SCH and adverse outcomes, or those among different outcomes, was not addressed in this study. For example, GH, especially preeclampsia, can raise the TSH level [61]. Hence, this study could not determine whether SCH caused the increased rate of GH or vice versa. Furthermore, preeclampsia is a major cause of IUGR due to reduced nutrition transportation from the placenta [62,63]. Thus, this study could not determine whether the presence of SCH increases the risk of GH, which is further related to an increased incidence of IUGR, or whether SCH is directly related to the increased prevalence of IUGR.

Our results suggest that SCH is associated with several fetal and infant defects, as well as maternal dysfunction. Further investigation of the effects of thyroid function screening and prospective medical intervention on SCH in a randomized, placebo-controlled experiment could aid the verification of these associations with adverse obstetric outcomes.

### Author Contributions
Conceived and designed the experiments: LC CZ XL. Performed the experiments: LC WD JD QZ GS HY EY QC LY. Analyzed the data: LC CZ XL. Contributed reagents/materials/analysis tools: XL. Contributed to the writing of the manuscript: LC CZ XL. Improved the English of the manuscript: XL.

### References
1. Lauerberg P, Andersen SL, Pedersen IB, Andersen S, Carle A (2013) Screening for overt thyroid disease in early pregnancy may be preferable to searching for small aberrations in thyroid function tests. Clin Endocrinol (Oxf) 79: 297–304.
2. Reid SM, Middleton P, Cossich MC, Crowther CA (2010) Interventions for clinical and subclinical hypothyroidism in pregnancy. Cochrane Database Syst Rev: CD000752.
3. Rashid M, Rashid MH (2007) Obstetric management of thyroid disease. Obstet Gynecol Surv 62: 680–688; quiz 691.
4. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, et al. (2012) Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 18: 998–1029.
5. Pop VJ, Kuiperus JL, van Baar AL, Verkerk G, van Son MM, et al. (1999) Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. Clin Endocrinol (Oxf) 50: 149–155.
6. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, et al. (1999) Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 341: 549–555.
7. Julvez J, Alvarez-Pedrero M, Rebagliato M, Murcia M, Forns J, et al. (2013) Thyroxine levels during pregnancy in healthy women and early child neurodevelopment. Epidemiology 24: 150–157.
8. Oppenheimer JH, Schwartz HL (1997) Molecular basis of thyroid hormone-dependent brain development. Endocrine Reviews 18: 462–475.
9. Garnier R (2009) Thyroid diseases in pregnancy. Curr Opin Obstet Gynecol 21: 501–507.
10. Lazarus JH (2011) Thyroid function in pregnancy. Br Med Bull 97: 137–148.
11. Sahay RK, Nagesh VS (2012) Hypothyroidism in pregnancy. Indian J Endocrinol Metab 16: 364–370.
12. Cleary-Goldman J, Malone FD, Lambert-Messerlian G, Sullivan L, Canick J, et al. (2008) Maternal thyroid hypofunction and pregnancy outcome. Obstet Gynecol 112: 85–92.
13. Casey BM, Dashe JS, Spong CY, McIntire DD, Leveno KJ, et al. (2007) Perinatal significance of isolated maternal hypothyroxinemia identified in the first half of pregnancy. Obstet Gynecol 109: 1129–1135.
14. Nelson DR, Casey BM, McIntire DD, Cunningham FG (2014) Subsequent pregnancy outcomes in women previously diagnosed with subclinical hypothyroidism. Am J Perinatol 31: 77–84.
15. Tutela CM, Casey BM, McIntire DD, Cunningham FG (2012) Relationship of subclinical thyroid disease to the incidence of gestational diabetes. Obstet Gynecol 119: 983–988.
16. Casey BM, Dashe JS, Wells CE, McIntire DD, Byrd W, et al. (2005) Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol 105: 239–245.
17. Wilson KL, Casey BM, McIntire DD, Halfvorsn LM, Cunningham FG (2012) Subclinical thyroid disease and the incidence of hypertension in pregnancy. Obstet Gynecol 119: 315–320.
18. American College of O, Gynecology (2002) ACOG practice bulletin. Thyroid disease in pregnancy. Number 37, August 2002. American College of Obstetrics and Gynecology. Int J Gynaecol Obstet 79: 171–190.
19. De Groot L, Ahaslewi M, Alexander ER, Amino N, Barbour L, et al. (2012) Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97: 2543–2565.
20. Lu XM, Chen L, Yang H, Du WJ, Lin H, et al. (2012) Trimester specific reagents/materials/analysis tools: XL. Contributed to the writing of the manuscript: LC CZ XL. Improved the English of the manuscript: XL.
Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34: 2159–2199.

22. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, et al. (2011) Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 57: e1–e7.

23. Oppenheimer L, Society of O, Gynaecologists of C (2007) Diagnosis and management of placenta previa. J Obstet Gynecol Can 29: 261–273.

24. Menon R, Fortunato SJ (2007) Infection and the role of inflammation in preterm premature rupture of the membranes. Best Pract Res Clin Gynaecol 21: 467–478.

25. Polzin VJ, Brady K (1998) The etiology of premature rupture of the membranes. Clin Obstet Gynecol 41: 810–816.

26. Di Renzo GC, Koura LC, European Association of Perinatal Medicine-Study Group on Preterm B (2006) Guidelines for the management of spontaneous preterm labor. J Perinat Med 34: 359–366.

27. G.Y H (2003) Abnormal Pregnancy Time. In: Le J, Xie X, Feng YJ, editors. Intergenerational Joint Mission Between Parents and Grandparents. Journal of Reproductive health. Endocr Rev 31: 702–755.

28. Resnik R (2002) Intrauterine growth restriction. Obstet Gynecol 99: 490–496.

29. Wollmann HA (1998) Intrauterine growth restriction: definition and etiology. Horm Res 49 Suppl 2: 1–6.

30. Qin C, Zhou M, Callaghan WM, Posner SF, Zhang J, et al. (2012) Clinical indications and determinants of the rise of cesarean section in three hospitals in rural China. Matern Child Health J 16: 1404–1490.

31. Kjos SL, Leung A, Henry OA, Victor MR, Paul RH, et al. (1995) Antepartum surveillance in diabetic pregnancies: predictors of fetal distress in labor. Am J Obstet Gynecol 173: 1532–1539.

32. Schieve LA, Meikle SF, Ferre C, Peterson HB, Jeng G, et al. (2002) Low and very low birth weight in infants conceived with use of assisted reproductive technology. N Engl J Med 346: 731–737.

33. Smith GC, Frentz RC (2007) Stillbirth. Lancet 370: 1715–1725.

34. Vaidya B, Anthony S, Bilous M, Shields B, Drury J, et al. (2007) Detection of subclinical hypothyroidism undergoing assisted reproduction technologies: a prospective population-based cohort study. J Clin Endocrinol Metab 92: 203–207.

35. Horacek J, Spitalnikova S, Dlabalova B, Malirova E, Vizda J, et al. (2010) Risk-Based Screening for Thyroid Dysfunction during Pregnancy. J Pediatr Endocrinol Metab 23: 79–85.

36. Goh ECL (2006) Raising the Precious Single Child in Urban China-An Intergenerational Joint Mission Between Parents and Grandparents. Journal of Reproductive health. Endocr Rev 31: 702–755.

37. Stagnaro-Green A, Pearce E (2012) Thyroid disorders in pregnancy. Nat Rev Endocrinol 8: 624.

38. Su PY, Huang K, Hao JH, Xu YQ, Yan SQ, et al. (2011) Maternal thyroid function in the first twenty weeks of pregnancy and subsequent fetal and infant development: a prospective population-based cohort study in China. J Clin Endocrinol Metab 96: 3254–3241.

39. Velkeniers B, Van Meerhaeghe A, Poppe K, Unuane D, Tournaye H, et al. (2007) Neurodevelopmental outcome of children with intrauterine growth retardation: a longitudinal, 10-year prospective study. J Child Neurol 22: 580–587.

40. Fattal-Valevski A, Leitner Y, Kutai M, Tal-Posener E, Tomer A, et al. (2012) Neurodevelopmental outcome in children with intrauterine growth retardation: a 3-year follow-up. J Child Neurol 14: 724–727.

41. Idris I, Sinivasan R, Stum A, Page KG (2005) Maternal hypothyroidism in early and late gestation: effects on neonatal and obstetric outcome. Clin Endocrinol (Oxf) 63: 560–565.

42. Mannisto T, Vaaramaki M, Ponta A, Hartikainen AL, Ruokonen A, et al. (2009) Perinatal outcome of children born to mothers with thyroid dysfunction or antibodies: a prospective population-based cohort study. J Clin Endocrinol Metab 94: 772–779.

43. Su PY, Huang K, Hao JH, Xu YQ, Yan SQ, et al. (2011) Maternal thyroid dysfunction in the first twenty weeks of pregnancy and subsequent fetal and infant development: a prospective population-based cohort study in China. J Clin Endocrinol Metab 96: 3254–3241.

44. Fletcher AK, Weetman AP (1998) Hypertension and hypothyroidism. J Hum Hypertens 12: 79–82.

45. Danzi S, Klein I (2012) Thyroid hormone and the cardiovascular system. Med Clin North Am 96: 257–261.

46. Sheffield JS, Cunningham FG (2004) Thyrotoxicosis and heart failure that complicate pregnancy. Am J Obstet Gynecol 190: 211–217.

47. Danzi S, Klein I (2003) Thyroid hormone and blood pressure regulation. Curr Hypertens Rep 5: 513–520.

48. Rodondi N, Nesman AB, Vittinghoff E, de Rekeneire N, Satterfield S, et al. (2005) Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med 165: 2460–2466.

49. Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, et al. (2003) Impaired endothelium-dependent vasodilation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 88: 3731–3737.

50. Tiros H, Benshalom-Tirosh N, Novack L, Press F, Beer-Weisel R, et al. (2013) Hypothyroidism and diabetes mellitus - a risky dual gestational endocrinopathy. PeerJ 1: e32.

51. Davis LE, Leveno KJ, Cunningham FG (1980) Hypothyroidism complicating pregnancy. Obstet Gynecol 72: 108–112.

52. Leung AS, Millar IK, Koopings PP, Montoro M, Mestman JH (1993) Perinatal outcome in hypothyroid pregnancies. Obstet Gynecol 81: 349–353.

53. Lipper E, Lee K, Gartner LM, Grellong P (1981) Determinants of neurobehavioral outcome in low-birth-weights infants. Pediatrics 67: 562–565.

54. Leitner Y, Fattal-Valevski A, Geva R, Eshel R, Toledano-Alhadef H, et al. (2007) Neurodevelopmental outcome of children with intrauterine growth retardation: a longitudinal, 10-year prospective study. J Child Neurol 22: 580–587.

55. Fattal-Valevski A, Leitner Y, Kutai M, Tal-Posener E, Tomer A, et al. (1999) Neurodevelopmental outcome in children with intrauterine growth retardation: a 3-year follow-up. J Child Neurol 14: 724–727.

56. Idris I, Sinivasan R, Stum A, Page KG (2005) Maternal hypothyroidism in early and late gestation: effects on neonatal and obstetric outcome. Clin Endocrinol (Oxf) 63: 560–565.

57. Mannisto T, Vaaramaki M, Ponta A, Hartikainen AL, Ruokonen A, et al. (2009) Perinatal outcome of children born to mothers with thyroid dysfunction or antibodies: a prospective population-based cohort study. J Clin Endocrinol Metab 94: 772–779.

58. Su PY, Huang K, Hao JH, Xu YQ, Yan SQ, et al. (2011) Maternal thyroid dysfunction in the first twenty weeks of pregnancy and subsequent fetal and infant development: a prospective population-based cohort study in China. J Clin Endocrinol Metab 96: 3254–3241.

59. Velkeniers B, Van Meerhaeghe A, Poppe K, Unuane D, Tournaye H, et al. (2013) Levothyroxine treatment and pregnancy outcome in women with subclinical hypothyroidism undergoing assisted reproduction technologies: systematic review and meta-analysis of RCTs. Hum Reprod Update 19: 251–256.

60. Cooper DS, Biondi B (2012) Subclinical thyroid disease. Lancet 379: 1142–1154.

61. North RA, Taylor RN (2009) Subclinical hypothyroidism after pre-eclampsia. British Medical Journal 339.

62. Myatt L (2006) Placental adaptive responses and fetal programming. Journal of Perinatal 29: 680–684.